Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Tablet Health vs yourEra

Tablet Health
Graded #495

Lower grade

vs+36.199999999999996
yourEra
Graded #13

Higher grade

The verdict

yourEra takes it — 83.8/100 to 47.6/100.

yourEra grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A both-molecule compounded program that publishes its prices up front — semaglutide $199/mo, tirzepatide $299/mo — across a 50-state clinician network, with an optional coaching-plus-labs membership and a NAD+/microdosing menu on the side.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueyourEra +37
45
82
Dose & formulationyourEra +31
51
82
Clinical oversightyourEra +48
37
85
Labs & monitoringyourEra +35
50
85
FulfillmentyourEra +29
57
86
Contract termsyourEra +30
55
85
Tablet Health · left baryourEra · right bar

The numbers

MetricTablet HealthyourEra
WeighScore47.6/10083.8/100
GradeCB
Scorecard rank#495#13
SemaglutideNot disclosed$199/mo
TirzepatideNot disclosed$299/mo
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
Tablet Health

Graded #495 · C

Strengths

  • LegitScript Certified
  • Four named compounding pharmacy partners (Pharmacy Hub, Epiq Scripts, Dr. TelX, Emerad), none with FDA warning letters
  • Oral GLP-1 option for both semaglutide and tirzepatide — uncommon in compounded telehealth
  • Mid-tier pricing starting $179–$299/mo across all four product variants
  • No commitment — cancel anytime

Where it loses points

  • States served not published — you must complete the intake quiz to learn eligibility
  • No founder, CEO, medical director, or pharmacist-in-charge named anywhere
  • No BBB profile found
  • Its Queens NYC pharmacy is 'opening soon' — all dispensing currently routes through external partners
  • FDA issued this company a warning letter dated 19 March 2025; the letter is public in FDA's warning-letter database
yourEra

Graded #13 · B

Strengths

  • Transparent, publicly listed pricing — many compounded competitors hide price behind a quiz
  • Both semaglutide and tirzepatide, not a single-drug menu, plus NAD+ and microdosing lines
  • Markets a 50-state licensed-clinician network; no insurance required, HSA/FSA accepted
  • Optional yourEra Optimum membership adds 1:1 coaching, a nutritionist, at-home lab draws and wearables

Where it loses points

  • Compounded semaglutide/tirzepatide are not FDA-approved (not the same as Wegovy/Ozempic/Zepbound)
  • Mid-market pricing ($199 sema / $299 tirz) — above the cheapest compounders
  • No brand-name lane and no oral route — weekly injectable only
  • Thin independent footprint; the 50-state and efficacy claims are self-reported

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard